WO1991002529A3 - Produit et methode pour tuer les cellules anormales chez les vertebres - Google Patents

Produit et methode pour tuer les cellules anormales chez les vertebres Download PDF

Info

Publication number
WO1991002529A3
WO1991002529A3 PCT/US1990/004469 US9004469W WO9102529A3 WO 1991002529 A3 WO1991002529 A3 WO 1991002529A3 US 9004469 W US9004469 W US 9004469W WO 9102529 A3 WO9102529 A3 WO 9102529A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
product
diaminoacridine
proflavine
concentrations
Prior art date
Application number
PCT/US1990/004469
Other languages
English (en)
Other versions
WO1991002529A2 (fr
Inventor
John Bennett Kizer
Original Assignee
John Bennett Kizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John Bennett Kizer filed Critical John Bennett Kizer
Publication of WO1991002529A2 publication Critical patent/WO1991002529A2/fr
Publication of WO1991002529A3 publication Critical patent/WO1991002529A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Abstract

Produit et méthode pour tuer des tissus anormaux ou des cellules du sang anormales et indésirables tout en sauvant les tissus ou les cellules normales. Un composé de diaminoacridine, de proflavine dans une version préférée, lyse les cellules anormales pendant une période de temps variant de 6 heures à 2 jours au cours de laquelle les cellules concernées sont exposées à la diaminocridine, à des concentrations d'au moins 1 mg/kg de la masse corporelle. Des concentrations de diaminoacridine d'au moins 15 mg/kg de la masse corporelle sont sans danger pour l'homme, provoquant cependant une hypersensibilité passagère à la lumière du soleil. De manière spécifique, la proflavine est un traitement utile contre le cancer et, en théorie, elle pourrait être utile pour lutter contre le SIDA, l'arthrite rhumatismale et le psoriasis.
PCT/US1990/004469 1989-08-14 1990-08-09 Produit et methode pour tuer les cellules anormales chez les vertebres WO1991002529A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39351489A 1989-08-14 1989-08-14
US393,514 1989-08-14

Publications (2)

Publication Number Publication Date
WO1991002529A2 WO1991002529A2 (fr) 1991-03-07
WO1991002529A3 true WO1991002529A3 (fr) 1991-04-04

Family

ID=23554997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/004469 WO1991002529A2 (fr) 1989-08-14 1990-08-09 Produit et methode pour tuer les cellules anormales chez les vertebres

Country Status (1)

Country Link
WO (1) WO1991002529A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2704856B1 (fr) * 1993-05-04 1995-08-04 Pf Medicament Nouveaux dérivés de la diméthylamino-3 acridine.
GB9321558D0 (en) * 1993-10-19 1993-12-08 Radopath Ltd Anti-viral agents
GB2319474A (en) * 1993-10-19 1998-05-27 Radopath Ltd Anti-viral agents
FR2711527A1 (fr) * 1993-10-22 1995-05-05 Richard Laboratoire M Utilisation de l'acriflavine comme agent anti HIV.
US6221882B1 (en) * 1997-07-03 2001-04-24 University Of Iowa Research Foundation Methods for inhibiting immunostimulatory DNA associated responses
DE19731238A1 (de) * 1997-07-21 1999-01-28 Zimmer Peter Verwendung von Aminoacridinen zur Behandlung solider Tumoren, Metastasen und Lymphomen
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
JPWO2006095897A1 (ja) 2005-03-08 2008-08-21 武田薬品工業株式会社 スクリーニング方法
RU2349311C1 (ru) * 2007-08-02 2009-03-20 Михаил Владимирович Кутушов Применение дериватов нафталина в качестве средств для лечения онкологических заболеваний
WO2018210238A1 (fr) * 2017-05-15 2018-11-22 北京大学 Dérivé d'acridine fusionné agissant sur la dectine-1 et son utilisation
CN112336864A (zh) * 2019-08-08 2021-02-09 厦门大学 原黄素在肺癌治疗中的应用
WO2023116397A1 (fr) * 2021-12-25 2023-06-29 珞达生物医药(苏州)有限公司 Médicament activant l'immunité innée et son utilisation
WO2023242104A1 (fr) 2022-06-13 2023-12-21 KHR Biotec GmbH Dérivés de diaminoacridine en tant qu'inhibiteurs de ras

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Arzneimittelforschung, Vol. 25, No. 10, 1975, H. OSSWALD: "Potentiated Chemotherapeutic Activity of 3,6-Diamino-10-Methyl-Acridinium by Combination with Glycine or DL-alpha-Alanine on the Ehrlich Carcinoma", pages 1608-1609 see page 1609, left-hand column, line 31 - right-hand column, line 32 *
Cancer Chemother. Pharmacol., Vol. 1, No. 1, 1978, Springer Verlag, G. MATHE et al.: "New Cancer Chemotherapy Drugs in Europe", pages 5-13 see page 9, right-hand column, lines 50-54 *
Eur. J. Cancer, Vol. 16, No. 9, 1980, Pergamon Press Ltd, (GB), I.G.C. ROBERTSON et al.: "Inhibition of T4 Bacteriophage Yield by 9-Anilino-Acridines; Comparison with in Vivo Anti-Tumour Activity", pages 1133-1140 see page 1134, right-hand column, lines 7-14; page 1136, table I, Compounds 25-38 *
J. Inst. Chemists (India), Vol. 60, No. 2, March 1988, N.G. CHAKRABORTY et al.: "Chemical Modification of Tumor Cell Surface with Different Acridine Dyes", pages 51-52 see page 51, lines 9-20 *
J. Med. Chem. Vol. 30, No. 4, 1987, American Chemical Society, W.A. DENNY et al.: "Potential Antitumor Agents. 49. 5-Substituted Derivatives of N-(2-(Dimethylamino) Ethtyl) -9-Aminoacridine-4-Carboxamide with in Vivo Solid-Tumor Activity", pages 658-663 see table 1, Compound 14 *

Also Published As

Publication number Publication date
WO1991002529A2 (fr) 1991-03-07

Similar Documents

Publication Publication Date Title
WO1991002529A3 (fr) Produit et methode pour tuer les cellules anormales chez les vertebres
MX9707732A (es) Compuestos triciclicos utiles en el tratamiento de desordenes proliferativos de celulas.
CS141387A2 (en) Microbicide
AU576365B2 (en) Collagen and or fibrinogen as carrier of drugs for their introduction into cellular lesion areas
CA2213339A1 (fr) Procede de traitement de la depletion de l'adenosine
CA2158475A1 (fr) Composition et methode pour la reduction de facteurs biologiquement actifs
CA2017705A1 (fr) Prothese valvulaire provenant du porc
CA2029420A1 (fr) Compositions pharmaceutiques et methodes permettant d'inhiber la reaction de maillard
AU5046693A (en) Use of purified surface modifiers to prevent particle aggregation during sterilization
AU8138687A (en) Agents for combating pests and plant treatment agents
MY106528A (en) Method of treating impotence.
PL310474A1 (en) Application of rilusole in treating neuro-aids diseases
MY102648A (en) Pharmacological / cosmetic preparation
GB2210789A (en) Topical application for skin care
AU669946B2 (en) Lanolin/lanolin acid ester skin treatment composition
CA2150714A1 (fr) Modification des concentrations de syndecan en vue de stimuler la differenciation cellulaire
EP0357646A4 (en) Treatment of aged skin with oral 13-cis-retinoic acid
AU7609094A (en) Treatment and prophylaxis of diseases caused by parasites or bacteria
GB9316004D0 (en) Improvements in or relating to the treatment of sickle cell disease
CA2132745A1 (fr) Nouveaux agents cardioprotecteurs
RU93003584A (ru) Способ лечения синдрома поликистозных яичников
CA2394365A1 (fr) Utilisation d'un regulateur de croissance vegetale a base de semicarbazone pour ameliorer le rendement des cultures
AU4890885A (en) Improvements in or relating to the treatment of trees and bushes
EP0765662A4 (fr) Composition inhibitrice de la croissance du virus vih
AU1966988A (en) Ophthalmic agent and related compositions and method for treatment of the cornea

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

NENP Non-entry into the national phase in:

Ref country code: CA